Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:1561-73.

Slides:

Advertisements

Similar presentations

THE DIABETES PREVENTION PROGRAM RESEARCH GROUP*

Advertisements

Trial profile Fox K et al. Lancet 2008;372:

ASTEROID A Study To evaluate the Effect of Rosuvastatin On Intravascular ultrasound- Derived coronary atheroma burden.

Downloaded from Slide 1 Dual Inhibition of Two Sources of Cholesterol: Absorption and Production in Patients with Type 2 Diabetes.

BackgroundBackground HDL-C levels are inversely related to CV event rates. HDL-C levels are inversely related to CV event rates. Torcetrapib, a cholesteryl.

Enrollment and Outcomes J.J.P. Kastelein, et al. N Engl J Med 2008;358:1431.

Philip J. Barter, et al. Circulation 2011;124:

Glynn RJ, et al. N Engl J Med 2009 Mar 29 [Epub ahead of print]

Comparison of the Progression of Coronary Atherosclerosis for Two High Efficacy Statin Regimens with Different HDL Effects: SATURN Study Results SJ Nicholls,

Flow of Participants Through the Trial David J. A. Jenkin et al. JAMA 2008;300:

Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy Kahn SE, et al. (ADOPT Study Group) N Engl J Med 2006;355: Steven E. Kahn,

Ho PM, et al. JAMA 2009;301: Baseline Characteristics of Patients Taking Clopidogrel After Hospital Discharge a Ho PM, et al. JAMA 2009;301:

SATURN: Objective To compare the effects of rosuvastatin 40 mg versus atorvastatin 80 mg on progression of coronary atherosclerosis assessed by intravascular.

Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:

Effect of the Renin Inhibitor Aliskiren on Progression of Coronary Atherosclerosis: AQUARIUS Study Results SJ Nicholls, GL Bakris, JJP Kastelein, V Menon,

APS. Investigators & Sites APS Background Study Hypotheses.

Slide Source: Lipids Online Slide Library ASTEROID Population at Baseline (n=507) Patients Completing (n=349) Patients Not Completing.

Effect of on Oral Agent Inducing ApoA-I Synthesis on Progression of Coronary Atherosclerosis: Results of the ASSURE Study SJ Nicholls, CM Ballantyne, PJ.

Baseline Characteristics of the Patient Population (n=525) Colin Berry, et al. Circulation 2007;115:

Hsia J et al. J Am Coll Cardiol 2011;57: Baseline Characteristics by Treatment Group and Attained LDL-C Hsia J et al. J Am Coll Cardiol 2011;57:

PERISCOPE Comparison of Pioglitazone vs. Glimepiride on Progression of Coronary Atherosclerosis in Patients with Type 2 Diabetes Stephen J. Nicholls MBBS.

Study Flow Diagram Holvoet P, et al. JAMA 2008;299: The Figure shows the selection of 1889 participants who did not have metabolic syndrome at year.

Trial profile The FIELD study investigators, Lancet Published online November 14, 2005.

Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea A.

Flow Diagram of Identification of Randomized Trials for Inclusion Goran Bjelakovic, et al. JAMA. 2007;297:

Downloaded from Slide 1 Dual Inhibition of Two Sources of Cholesterol: Absorption and Production Results of a Clinical Trial.

Slide Source: Lipids Online Slide Library Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Nissen SE et al. JAMA.

Patients’ Assignments,Values at Screening, and Baseline Efficacy and Safety Values - PartI JP Després, N Engl J Med 2005; 353:

Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Varespladib and Cardiovascular Events in Patients.

Date of download: 7/5/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of High vs Low Glycemic Index of Dietary Carbohydrate.

R1. 이정미 / prof. 김우식. INTRODUCTION Reduction in low-density lipoprotein (LDL) cholesterol levels has proved to be highly effective in reducing rates of.

The American College of Cardiology Presented by Dr. Steven E. Nissen

Neal B, et al. Diabetes Care 2015;38:403–411

Treatment LDL-C: baseline (mg/dL) LDL-C: 24 mo (mg/dL) p

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

GAUSS-3 Trial design: Patients with objective evidence of intolerance to statin agents were randomized in a 2:1 fashion to either evolocumab 420 mg subcutaneously.

PAD Patients vs Post-ACS Patients:

The Safety and Efficacy of Full vs

PCP Perspectives Clinical Considerations in Hyperkalemia

GLAGOV Trial design: Patients with CAD and elevated LDL cholesterol on statin therapy were randomized to subcutaneous evolocumab (n = 484) vs. subcutaneous.

Effect of on Oral Agent Inducing ApoA-I Synthesis on Progression of Coronary Atherosclerosis: Results of the ASSURE Study SJ Nicholls, CM Ballantyne, PJ.

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients Evan Stein, MD, Harold Bays, MD, Michael Koren,

Trial profile John A Dormandy et al. Lancet 2005;366:

Fellström BC, et al. N Engl J Med 2009;360:1455-7

Selmer R, et al. Br J Clin Pharmacol 2009;67:355-62

Efficacy and Safety of Elbasvir/Grazoprevir in Treatment-Naïve patients with Chronic HCV GT 1, GT 4 and GT 6 Infection (C-CORAL): A Phase III Randomized.

Shifting Currents in Hyperkalemia Management 2015 in Review

Shifting Currents in Hyperkalemia Management 2015 in Review

Efficacy and safety of niacin/laropiprant

Fig. 1. MAHALO clinical trial flowchart.

Hajer GR et al. Atherosclerosis 2009;202:216-24

Enrollment and Outcomes

Stephen J. Nicholls, MBBS, PhD; E

Flow of Patients Through the Trial

Characteristics of the Patients at Baseline*

Flow of Patients Through Trial

Study Participant Flow

Baseline Characteristics of the Patients and Use of Concomitant Medications – Part I Kaare Harald Bønaa, et al. N Engl J Med 2006;354:

Baseline Characteristics, Blood Pressures, and Laboratory Values

Patient Disposition James A. de Lemos et al. JAMA 2004; 292:

Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.

SOLID-TIMI 52 Trial design: Participants within 30 days of an acute coronary syndrome (ACS) were randomized to darapladib 160 mg daily (n = 6,504) versus.

Participation in Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Hisao Ogawa et al. JAMA 2008;300:

Disposition of Patients in the Atherogenic Dyslipidemia Study

Baseline demographics and clinical characteristics of 3,956 rosuvastatin-treated patients Donald G. Vidt, et al. Am J Cardiol 2006;97:1602–1606.

Flow of study participants

Glycemic control and body weight over 52 weeks.

© The Author(s) Published by Science and Education Publishing.

Changes of major clinical and biochemical characteristics at baseline and during follow-up in different groups. Changes of major clinical and biochemical.

Translating Data From Trial to Practice

Presentation transcript:

Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:

Baseline Demographic Characteristics and Medications at the Time of Randomization Nissen SE, et al. JAMA 2008;299:

Baseline and On-Treatment Vital Signs and Laboratory Values in Participants Completing the Trial (n=360) a Nissen SE, et al. JAMA 2008;299:

Changes in Mean Hemoglobin A1c, Fasting Plasma Glucose Levels, High-Density Lipoprotein Cholesterol, and C-Reactive Protein During the Trial (n = 360) Nissen SE, et al. JAMA 2008;299:

Baseline, Follow-up, and Change From Baseline in Intravascular Ultrasound End Points Nissen SE, et al. JAMA 2008;299:

Primary Efficacy Parameter (Percent Atheroma Volume) in Prespecified Subgroups Nissen SE, et al. JAMA 2008;299:

Change From Baseline in Intravascular Ultrasound End Points Using Imputed Values for Noncompleters Nissen SE, et al. JAMA 2008;299:

Clinical End Points, Adverse Events, Laboratory Abnormalities, and Reasons for Discontinuing Participation (Safety Population, n = 543) Nissen SE, et al. JAMA 2008;299: